Latest news with #ListingRule
Yahoo
26-06-2025
- Business
- Yahoo
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
Company in full compliance for continued listing MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. ('HCWB' or the 'Company') (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies to extend healthspan by targeting the link between chronic inflammation and disease, announced today that it has received notice from The Nasdaq Stock Market LLC ('Nasdaq') informing the Company that it has regained compliance with the Nasdaq Capital Market's minimum stockholders' equity requirement as required by Nasdaq Listing Rule 5550(b)(1) (the 'Equity Rule'). On June 24, 2025, HCWB received formal notice from Nasdaq confirming that the Company has satisfied the requirements of the Equity Rule. On May 13, 2025, the Company received formal notice from Nasdaq that it regained compliance with the bid price requirement in Listing Rule 5550(a)(2), the public float requirement in Listing Rule 5550(a)(4), and the market value of publicly held shares requirement in Listing Rule 5550(a)(5). Therefore, the Company now meets all Nasdaq Capital Market listing requirements for continued listing, and these matters are closed. About HCW Biologics: HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company's immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients' quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company's lead product candidate, HCW9302, was developed using the Company's legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics can be used to treat a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform, including HCW11-002, HCW11-006, HCW11-018 and HCW11-027. Further preclinical evaluation studies are currently being conducted for these three molecules the Company has selected based on promising early data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at Company Contact: Rebecca ByamCFOHCW Biologics
Business Upturn
25-06-2025
- Business
- Business Upturn
Rocky Mountain Chocolate Factory Regains Compliance with Nasdaq Listing Requirements
By GlobeNewswire Published on June 26, 2025, 01:05 IST DURANGO, Colo., June 25, 2025 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the 'Company', 'we', or 'RMCF'), America's ChocolatierTM and a leading franchiser of a premium chocolate and confectionary retail store concept, announced that it has regained compliance with Nasdaq Listing Rule 5250(c)(1) following the filing of its Annual Report on Form 10-K for the fiscal year ended February 28, 2025. Nasdaq Listing Rule 5250(c)(1) requires listed companies to file all required annual and quarterly reports with the SEC on a timely basis. On June 17, 2025, the Company received a notice from The Nasdaq Stock Market LLC ('Nasdaq') indicating that it was not in compliance with the Listing Rule due to the delayed filing of its Form 10-K. This was described more fully in the Company's Form 12b-25 Notification of Late Filing, filed with the Securities and Exchange Commission (the 'SEC') on May 27, 2025. The Company filed its Form 10-K on June 20, 2025, and subsequently received formal notice from Nasdaq on June 23, 2025, confirming that it had regained compliance. About Rocky Mountain Chocolate Factory, Inc. R ocky Mountain Chocolate Factory, Inc. is a leading franchiser of a premium chocolate and confectionary retail store concept. As America's ChocolatierTM, the Company has been producing an extensive line of premium chocolates and other confectionery products, including gourmet caramel apples since 1981. Headquartered in Durango, Colorado, Rocky Mountain Chocolate Factory is ranked among Entrepreneur's Franchise 500® for 2025 and Franchise Times' Franchise 400® for 2024. The Company and its franchisees and licensees operate nearly 260 Rocky Mountain Chocolate stores across the United States, with several international locations. The Company's common stock is listed on the Nasdaq Global Market under the symbol 'RMCF.' Investor ContactSean Mansouri, CFAElevate IR720-330-2829 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
10-06-2025
- Business
- Yahoo
Sify Technologies Ltd. Announces Non-Compliance with Nasdaq Listing Requirements due to Resignation of a Director
CHENNAI, India, June 10, 2025 (GLOBE NEWSWIRE) -- Sify Technologies Ltd. (Nasdaq: Sify) (the 'Company'), a leading integrated information communications technology (or ICT) Solutions and Services provider in India, notified the Nasdaq Stock Market ('Nasdaq') on May 21, 2025 that, consequent to the resignation of Dr. Ajay Kumar from the Company's Board of Directors (the 'Board'), the Company was in non-compliance with Nasdaq Listing Rule 5605(b)(1), requiring that the majority of the Board be composed of independent directors, and Nasdaq Listing Rule 5605(c)(2), requiring that there be at least three members of the Board's audit committee. Dr. Kumar resigned to take charge of a constitutional responsibility pursuant to the order of the Hon'ble President of India. The Company also indicated its intent to rely on the cure periods in Nasdaq Listing Rules 5605(b)(1)(A) and 5605(c)(4)(B). Further on June 5, 2025, the Company received a letter from the Listing Qualifications Department of Nasdaq indicating that, due to Dr. Kumar's resignation, the Company no longer complies with Nasdaq's independent director and audit committee requirements as set forth in Listing Rule 5605. The notice states that, consistent with Listing Rules 5605(b)(1)(A) and 5605(c)(4), the Company would be provided with a cure period to regain compliance. Such cure period will last until the earlier of the Company's next annual shareholders' meeting, or May 15, 2026; provided that, if the next annual shareholders' meeting is held before November 11, 2025, then the Company must evidence compliance no later than November 11, 2025. The Nasdaq notice has no immediate effect on the listing or trading of the Company's ADSs on the Nasdaq Capital Market. The Company is actively engaged in identifying and evaluating the appointment of another independent director to the Board to fill the vacancies created by Dr. Kumar's resignation and to regain compliance with the Nasdaq Listing Rules within the specified cure period. If at any time before the end of the cure period, the Company complies with the requirements, the Company must submit to Nasdaq documentation, including biographies of any new directors, evidencing compliance with the rules. In the event the Company does not regain compliance by the end of the cure period, Nasdaq will provide notice to the Company that its ADSs will be subject to delisting. At that time, the Company may appeal the Nasdaq staff's delisting determination to a Nasdaq Hearings Panel. Safe Harbor StatementThis release contains certain 'forward-looking statements' relating to the Company and its business. These forward-looking statements are often identified by the use of forward-looking terminology such as 'expects', 'intends', 'will', or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as expected, intended or planned. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's reports that are filed with the Securities and Exchange Commission and available on its website ( All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements. For a discussion of the risks associated with Sify's business, please see the discussion under the caption 'Risk Factors' in the company's Annual Report on Form 20-F for the year ended March 31, 2025, which has been filed with the United States Securities and Exchange Commission and is available by accessing the database maintained by the SEC at and Sify's other reports filed with the SEC. About Sify Technologies A multiple year award winner of the Golden Peacock from the Institute of Directors for Corporate Governance, Sify Technologies is India's most comprehensive ICT service & solution provider. With Digital and AI at the core of our solutions portfolio, Sify is focused on the changing ICT requirements of the emerging Digital economy and the resultant demands from large, mid and small-sized businesses. Sify's infrastructure comprising state-of-the-art Data Centers, the largest MPLS network, partnership with global technology majors and deep expertise in business transformation solutions modelled on the cloud, make it the first choice of start-ups, SMEs and even large Enterprises on the verge of a revamp. More than 10000 businesses across multiple verticals have taken advantage of our unassailable trinity of Data Centers, Networks and Digital services and conduct their business seamlessly from more than 1700 cities in India. Internationally, Sify has presence across North America, the United Kingdom and Singapore. Sify, Sify Technologies and are registered trademarks of Sify Technologies Limited. For further information, please contact: Sify Technologies LimitedPraveen KrishnaInvestor Relations & Public Relations+91 20:20 Media Nikhila Kesavan+91 Weber ShandwickLucia Domville+1-212 546-8260LDomville@ Sign in to access your portfolio
Business Insider
05-06-2025
- Business
- Business Insider
Liminatus Pharma regains Nasdaq listing compliance
The company states: 'On May 29, 2025, Liminatus Pharma (LIMN) received a notice from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025. On June 2, 2025, the Company filed the Form 10-Q with the U.S. Securities and Exchange Commission. On June 3, 2025, the Company received a letter from the Staff stating that the Company had regained compliance with the Listing Rule and that the matter is now closed.' Confident Investing Starts Here:
Business Upturn
03-06-2025
- Business
- Business Upturn
Semilux Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 20-F
Taipei, Taiwan, June 02, 2025 (GLOBE NEWSWIRE) — Semilux International Ltd. (NASDAQ:SELX) ('SELX' or the 'Company') announced that it received a delinquency notification letter on May 27, 2025 (the 'Deficiency Letter') from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the 'Nasdaq') notifying the Company that it is no longer in compliance with the Nasdaq Listing Rule 5250(c)(1) (the 'Listing Rule') for continued listing due to its failure to timely file its annual report on Form 20-F for the year ended December 31, 2024 (the 'Annual Report') with the U.S. Securities and Exchange Commission. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. In accordance with Nasdaq's listing rules, the Company has 60 calendar days after the Deficiency Letter to submit a plan to regain compliance with the Listing Rule. Following receipt of such plan, Nasdaq may, at its discretion, grant an extension of up to 180 calendar days from the Annual Report's due date, or until November 11, 2025, for the Company to regain compliance. The Company was not able to file the Annual Report by the prescribed deadline as extended pursuant to Rule 12b-25(b)(2)(ii) under the Securities Exchange Act of 1934 primarily due to additional time being required to finalize its financial statements and complete the preparation of the Annual Report for the fiscal year ended December 31, 2024. The Company continues to work diligently to complete the Annual Report and intends to file it with the SEC as soon as reasonably practicable. The Deficiency Letter has no immediate impact on the listing of the Company's ordinary shares on the Nasdaq Capital Market. This announcement is made in compliance with the Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a notification of deficiency. About Semilux International Ltd. Semilux is domiciled in the Cayman Islands and operates through its subsidiaries, Taiwan Color Optics, Inc. ('TCO') and Semilux Ltd. TCO is an optical and 3D sensing technology company that is primarily involved in the customization, design and supply of optical components and integrated chip for various industries including autonomous driving, intelligent lighting, as well as unmanned aerial vehicles. In collaboration with its clients, TCO conceptualizes and produces high precision optics and sensing modules that are specifically customized to clients' needs for ease of integration in overall design and production. Applications for TCO's products include automotive laser headlight systems, adaptive driving beams (ADB) as well as light detection and autonomous driving systems (LiDAR). More information can be found at: Safe Harbor Statement This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding SELX's expectations, intentions, strategies, and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements because of various important factors, including those described in the Company's most recent filings with the SEC. SELX assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the sections entitled but not limited to, 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and 'Risk Factors' in SELX's annual reports on Form 20-F and interim reports on Form 6-K filed with the SEC, as such factors may be updated from time to time in SELX's periodic filings with the SEC, which are accessible on the SEC's website at and at Investor Relations Contact: Email: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
